BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

24 related articles for article (PubMed ID: 19596263)

  • 1. p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies.
    Diakite B; Kassogue Y; Dolo G; Wang J; Neuschler E; Kassogue O; Keita ML; Traore CB; Kamate B; Dembele E; Nadifi S; Murphy RL; Doumbia S; Hou L; Maiga M
    BMC Med Genet; 2020 Oct; 21(1):206. PubMed ID: 33076844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis.
    Gonçalves ML; Borja SM; Cordeiro JA; Saddi VA; Ayres FM; Vilanova-Costa CA; Silva AM
    Springerplus; 2014; 3():749. PubMed ID: 26034701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter polymorphisms of miR-34b/c are associated with risk of gastric cancer in a Chinese population.
    Yang C; Ma X; Liu D; Wang Y; Tang R; Zhu Y; Xu Z; Yang L
    Tumour Biol; 2014 Dec; 35(12):12545-54. PubMed ID: 25190020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 codon 72 polymorphism and breast cancer risk: A meta-analysis.
    Hou J; Jiang Y; Tang W; Jia S
    Exp Ther Med; 2013 May; 5(5):1397-1402. PubMed ID: 23737888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma.
    Li L; Wu J; Sima X; Bai P; Deng W; Deng X; Zhang L; Gao L
    Tumour Biol; 2013 Jun; 34(3):1919-23. PubMed ID: 23504554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.
    Cheng H; Ma B; Jiang R; Wang W; Guo H; Shen N; Li D; Zhao Q; Wang R; Yi P; Zhao Y; Liu Z; Huang T
    Mol Biol Rep; 2012 Sep; 39(9):9265-74. PubMed ID: 22729912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein.
    Hoyos D; Greenbaum B; Levine AJ
    Cell Death Differ; 2022 May; 29(5):938-945. PubMed ID: 35383292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target.
    Cheung KJ; Horsman DE; Gascoyne RD
    Br J Haematol; 2009 Aug; 146(3):257-69. PubMed ID: 19500100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.
    Lind H; Ekstrøm PO; Ryberg D; Skaug V; Andreassen T; Stangeland L; Haugen A; Zienolddiny S
    Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2077-81. PubMed ID: 17932356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 mutation, allelism and survival in non-small cell lung cancer.
    Nelson HH; Wilkojmen M; Marsit CJ; Kelsey KT
    Carcinogenesis; 2005 Oct; 26(10):1770-3. PubMed ID: 15905205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 codon 72 polymorphism as a risk factor in the development of breast cancer.
    Papadakis EN; Dokianakis DN; Spandidos DA
    Mol Cell Biol Res Commun; 2000 Jun; 3(6):389-92. PubMed ID: 11032762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population.
    Sameer AS; Shah ZA; Syeed N; Banday MZ; Bashir SM; Bhat BA; Siddiqi MA
    Genet Mol Res; 2010 Apr; 9(2):651-60. PubMed ID: 20449797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 codon 72 polymorphisms in favorable histology Wilms tumors.
    Cost NG; Mitui M; Khokhar S; Wickiser JE; Baker LA; Rakheja D
    Pediatr Blood Cancer; 2012 Aug; 59(2):326-8. PubMed ID: 22052810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 mutations and Arg72Pro polymorphism in breast cancers.
    Denisov EV; Cherdyntseva NV; Litvyakov NV; Slonimskaya EM; Malinovskaya EA; Voevoda MI; Belyavskaya VA; Stegniy VN
    Cancer Genet Cytogenet; 2009 Jul; 192(2):93-5. PubMed ID: 19596263
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.